Treating neurological disorders by complement activation
Regenesance aims to develop new drug therapies for neurological disorders such as ALS and Myasthenia Gravis. This development is based on research findings from the lab of Prof. Baas at the Academic Medical Center in Amsterdam. Prof. Baas and his team found that damaged nerves activate, the complement system, a part of our innate immune system. This activation results in collateral damage to the nervous system and impedes regeneration.
Our immune system's normal reaction is to clean up damaged and dead nerve cells. Activation of the innate immune system plays an important role in this process. However, the formation of MAC (Membrane Attack Complex), the product of the terminal pathway, has detrimental effects.